Staidson Beijing BioPharmaceuticals Co Ltd represents a set of core values and a corporate philosophy centered around innovation, excellence, and customer satisfaction. The company is committed to advancing the field of biopharmaceuticals through cutting-edge research and development efforts. Staidson Beijing BioPharmaceuticals Co Ltd places a strong emphasis on quality and safety, ensuring that their products adhere to the highest international standards. By prioritizing collaboration and cultivating a diverse and talented workforce, the company aims to foster a culture of creativity and continuous improvement. Staidson Beijing BioPharmaceuticals Co Ltd strives to make a positive impact on patients' lives by delivering innovative and effective healthcare solutions.

Staidson Beijing BioPharmaceuticals Co Ltd is primarily present in China.

Staidson Beijing BioPharmaceuticals Co Ltd has achieved several significant milestones. The company successfully developed and launched groundbreaking pharmaceutical products, leading to substantial market recognition and revenue growth. Staidson Beijing BioPharmaceuticals Co Ltd also established strategic partnerships with renowned global biotech companies. Moreover, the company achieved regulatory approval for its innovative drugs, expanding its reach to a wider patient population. These milestones solidify Staidson Beijing BioPharmaceuticals Co Ltd's position as a key player in the biopharmaceutical industry, driving innovation and positively impacting healthcare outcomes.

Staidson Beijing BioPharmaceuticals Co Ltd is a renowned biopharmaceutical company based in Beijing, China. Established in (year), Staidson has a rich history and notable background in the healthcare industry. The company specializes in (specific area of expertise) and aims to develop innovative solutions for various medical conditions. With a strong focus on research and development, Staidson is committed to delivering high-quality pharmaceutical products that improve the lives of patients worldwide. Through strategic partnerships and a dedicated team of experts, the company consistently strives to stay at the forefront of advancements in the biopharmaceutical field.

The main competitors of Staidson Beijing BioPharmaceuticals Co Ltd in the market include leading pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, Merck & Co., and AstraZeneca. These established industry players have a strong presence and compete for market share in the pharmaceutical sector. Staidson Beijing BioPharmaceuticals Co Ltd faces intense competition from these renowned companies, which strive to develop innovative drugs, invest in research and development, and maintain global market dominance.

Staidson Beijing BioPharmaceuticals Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

The business model of Staidson Beijing BioPharmaceuticals Co Ltd focuses on the development, manufacturing, and commercialization of innovative pharmaceutical products. The company primarily operates in the biopharmaceutical industry and aims to address unmet medical needs by utilizing advanced technologies and scientific expertise. Staidson Beijing BioPharmaceuticals Co Ltd strives to create value for its stakeholders through research and development of novel drug candidates, strategic partnerships, and efficient commercialization. By offering high-quality pharmaceutical products, the company aims to improve patients' lives and contribute to advancements in healthcare.

Pašreizējais KGV Staidson Beijing BioPharmaceuticals Co nevar tikt aprēķināts.

KUV šobrīd Staidson Beijing BioPharmaceuticals Co nevar aprēķināt.

AlleAktien kvalitātes vērtējums Staidson Beijing BioPharmaceuticals Co ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu Staidson Beijing BioPharmaceuticals Co.

Pašlaik peļņa Staidson Beijing BioPharmaceuticals Co nevar tikt aprēķināta.

Staidson Beijing BioPharmaceuticals Co Ltd is a Chinese company specializing in the development and manufacturing of innovative biopharmaceuticals. Its business model includes various sectors, including research and development, production, and sales and marketing. The company focuses on the research and development of biopharmaceuticals based on protein and peptide drugs. The goal is to develop innovative products that are highly effective, well-tolerated, and flexible to improve therapy outcomes for patients. In the research and development sector, the company emphasizes collaboration and partnerships. Employees work closely with physicians, research institutes, and universities to explore and develop new technologies and drugs. The production sector is responsible for large-scale production of the developed drugs. The company employs state-of-the-art technologies and facilities to ensure high quality and efficiency. Compliance with production standards and quality controls is central. The sales and marketing sector is responsible for placing and promoting the products in the market. The company relies on effective market research and a comprehensive marketing program to increase awareness of its products. The offered products include monoclonal antibodies, recombinant proteins, peptide drugs, and antisense oligonucleotides. These biopharmaceutical products are used to treat cancer, autoimmune diseases, infections, and other illnesses. The company aims to achieve a leading position in China's biopharmaceutical industry and gain international recognition. It continuously invests in research and development, as well as modern production facilities and distribution channels. Overall, the business model of Staidson Beijing BioPharmaceuticals Co Ltd is focused on developing, manufacturing, and marketing innovative biopharmaceuticals to improve therapy outcomes for patients. The company relies on close collaboration between research, production, and sales experts, as well as the use of cutting-edge technologies and adherence to the highest quality standards.

Staidson Beijing BioPharmaceuticals Co izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Staidson Beijing BioPharmaceuticals Co vai uzņēmums nedod dividendes.

Staidson Beijing BioPharmaceuticals Co ISIN ir CNE100001237.

Staidson Beijing BioPharmaceuticals Co simbols ir 300204.SZ.

Pēdējo 12 mēnešu laikā Staidson Beijing BioPharmaceuticals Co maksāja dividendes 0,67 CNY apmērā. Tas atbilst aptuveni 7,38 % dividendes ražībai. Nākamajos 12 mēnešos Staidson Beijing BioPharmaceuticals Co plāno maksāt dividendes 0 CNY apmērā.

Staidson Beijing BioPharmaceuticals Co pašreizējā dividendu rentabilitāte ir 7,38 %.

Staidson Beijing BioPharmaceuticals Co maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos jūnijs, maijs, aprīlis, jūnijs.

Staidson Beijing BioPharmaceuticals Co pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CNY. Tas atbilst dividendes ražībai 0 %.

Staidson Beijing BioPharmaceuticals Co tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Staidson Beijing BioPharmaceuticals Co apmērā 0,668 CNY, kas tika izmaksāta 17.05.2019., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.05.2019..

Pēdējās dividendes izmaksa notika 17.05.2019..

Gadā 2023, Staidson Beijing BioPharmaceuticals Co izmaksāja 0 CNY dividendes.

Staidson Beijing BioPharmaceuticals Co dividendes tiek izmaksātas CNY.